… disease and the cancer therapy being administered. For those hematologic cancers in which
… Indeed, we recommend that anyone with a diagnosis of hematologic malignancy be tested …

… HIV-associated lymphomas and hematological malignancies, summarized in this chapter,
indicate a need to enhance the therapeutic approach to reduce mortality for these neoplasms …

… R-CHOP/R-EPOCH are the standard of care for HIV-associated diffuse … for HIV-associated
multicentric Castleman disease or primary effusion lymphoma. For those hematologic cancers …

… Specific haematological malignancies occur in different … data for haematological malignancies
from these regions are … from HIV-associated haematological malignancies worldwide. …

… For haematological malignancies, the most extensively studied immunotherapeutic agent
for targeting HIV-associated lymphomas in people with HIV is rituximab. Rituximab is a …

… of HIV-associated hematological malignancies, including the ones classically associated
with AIDS-related immunosuppression and also other hematological malignancies such as …

… Although the incidence of HIV-associated lymphomas decreased after the introduction of
effective combination antiretroviral therapy, they became the most common AIDS-related …

… In the modern cART era, standard treatments for HIV-associated lymphoma including stem
cell transplantation in relapsed/refractory disease mirror that of the general population. The …

… HIV associated hematologic malignancies is sparse from India. This study attempts to analyze
the spectrum and features of this disease at a tertiary cancer … of hematologic malignancy …

… Hematopoietic cell transplantation (HCT) has now been shown to be safe and effective for
selected HIV-infected patients with hematological malignancies. Autologous HCT is now the …